Writing Group Disclosures

Writing Group MemberEmploymentResearch GrantOther Research SupportSpeakers’ Bureau/HonorariaExpert WitnessOwnership InterestConsultant/Advisory BoardOther
Joseph A. HillUniversity of Texas Southwestern Medical CenterAHA; NIHNoneNoneNoneNoneNoneNone
Christine E. SeidmanHarvard Medical School and Brigham and Women’s HospitalHoward Hughes Medical Institute; Fondation Leducq; NIHNoneNoneNoneNoneNoneHoward Hughes Medical Institute
Reza ArdehaliUCLA David Geffen School of MedicineNIH*; CIRM*NoneNoneNoneNoneNoneNone
Kimberli Taylor ClarkeVanderbilt UniversityNoneNoneNoneNoneNoneNoneNone
Gregory J. del ZoppoUniversity of Washington Harborview Medical CenterBoehringer Ingelheim; NIH; NovartisNoneNoneNoneNoneBoehringer Ingelheim*None
Lee L. EckhardtUniversity of WisconsinNIHNoneNoneNoneNoneNoneNone
Kathy K. GriendlingEmory UniversityNIHNoneNoneNoneNoneNoneNone
Peter LibbyBrigham and Women’s HospitalNIHNovartisNoneNoneNoneAmgen*; AstraZeneca*; Esperion Therapeutics*; Ionis Pharmaceuticals*; Kowa Pharmaceuticals*; Novartis*; Pfizer*; Sanofi Regeneron*; XBiotech, Inc*; Athera Biotechnologies*; Corvidia Therapeutics*; DalCor Pharmaceuticals*; Interleukin Genetics*; Medimmune*; Olatec Therapeutics*Brigham and Women’s Hospital; Harvard Medical School
Dan M. RodenVanderbilt University School of Medicine, Pharmacology, and Biomedical InformaticsNIHNoneNoneNoneNoneNoneNone
Hesham A. SadekUT Southwestern Medical CenterNIH; NASANoneNoneNoneNoneNoneNone
Douglas E. VaughanNorthwestern UniversityNHLBINoneNoneMerck 2016 defense; Vioxx litigationNoneAstraZeneca*None
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.